Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with or without Lenvatinib in 1L R/M HNSCC (LEAP-010)
NCT04199104Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of lenvatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Merck & Co.. Started Feb 2020; status: completed.
02
Drugs
lenvatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04199104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199104.